vs

Side-by-side financial comparison of FIRST US BANCSHARES, INC. (FUSB) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $10.4M, roughly 1.2× FIRST US BANCSHARES, INC.). FIRST US BANCSHARES, INC. runs the higher net margin — 20.4% vs -1398.3%, a 1418.8% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 7.1%). FIRST US BANCSHARES, INC. produced more free cash flow last quarter ($9.1M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 2.6%).

First Citizens Bancshares, Inc. is a bank holding company based in Raleigh, North Carolina and one of the largest banks in the United States. Its primary subsidiary is First Citizens Bank, which operates over 500 branches in 23 states. A second subsidiary is Silicon Valley Bank, which operates 39 offices in 15 states.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

FUSB vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.2× larger
RNA
$12.5M
$10.4M
FUSB
Growing faster (revenue YoY)
RNA
RNA
+427.0% gap
RNA
434.0%
7.1%
FUSB
Higher net margin
FUSB
FUSB
1418.8% more per $
FUSB
20.4%
-1398.3%
RNA
More free cash flow
FUSB
FUSB
$166.0M more FCF
FUSB
$9.1M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
2.6%
FUSB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FUSB
FUSB
RNA
RNA
Revenue
$10.4M
$12.5M
Net Profit
$2.1M
$-174.4M
Gross Margin
Operating Margin
28.1%
-1513.5%
Net Margin
20.4%
-1398.3%
Revenue YoY
7.1%
434.0%
Net Profit YoY
24.2%
-117.0%
EPS (diluted)
$0.36
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FUSB
FUSB
RNA
RNA
Q4 25
$10.4M
Q3 25
$10.5M
$12.5M
Q2 25
$10.3M
$3.8M
Q1 25
$9.8M
$1.6M
Q4 24
$9.7M
$3.0M
Q3 24
$10.1M
$2.3M
Q2 24
$10.0M
$2.0M
Q1 24
$9.9M
$3.5M
Net Profit
FUSB
FUSB
RNA
RNA
Q4 25
$2.1M
Q3 25
$1.9M
$-174.4M
Q2 25
$155.0K
$-157.3M
Q1 25
$1.8M
$-115.8M
Q4 24
$1.7M
$-102.3M
Q3 24
$2.2M
$-80.4M
Q2 24
$2.1M
$-70.8M
Q1 24
$2.1M
$-68.9M
Operating Margin
FUSB
FUSB
RNA
RNA
Q4 25
28.1%
Q3 25
23.9%
-1513.5%
Q2 25
1.6%
-4448.7%
Q1 25
23.8%
-8360.9%
Q4 24
23.8%
-4069.6%
Q3 24
29.2%
-4200.9%
Q2 24
27.4%
-4040.4%
Q1 24
27.8%
-2178.6%
Net Margin
FUSB
FUSB
RNA
RNA
Q4 25
20.4%
Q3 25
18.4%
-1398.3%
Q2 25
1.5%
-4089.3%
Q1 25
18.1%
-7360.0%
Q4 24
17.6%
-3439.5%
Q3 24
22.0%
-3441.7%
Q2 24
21.2%
-3461.8%
Q1 24
21.3%
-1943.4%
EPS (diluted)
FUSB
FUSB
RNA
RNA
Q4 25
$0.36
Q3 25
$0.32
$-1.27
Q2 25
$0.03
$-1.21
Q1 25
$0.29
$-0.90
Q4 24
$0.29
$-0.80
Q3 24
$0.36
$-0.65
Q2 24
$0.34
$-0.65
Q1 24
$0.34
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FUSB
FUSB
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$73.5M
$350.2M
Total DebtLower is stronger
$10.9M
Stockholders' EquityBook value
$105.6M
$1.9B
Total Assets
$1.2B
$2.1B
Debt / EquityLower = less leverage
0.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FUSB
FUSB
RNA
RNA
Q4 25
$73.5M
Q3 25
$54.7M
$350.2M
Q2 25
$54.0M
$243.9M
Q1 25
$56.0M
$254.2M
Q4 24
$47.2M
$219.9M
Q3 24
$82.3M
$370.2M
Q2 24
$58.2M
$575.8M
Q1 24
$60.2M
$471.4M
Total Debt
FUSB
FUSB
RNA
RNA
Q4 25
$10.9M
Q3 25
$10.9M
Q2 25
$10.9M
Q1 25
$10.9M
Q4 24
$10.9M
Q3 24
$10.9M
Q2 24
$10.8M
Q1 24
$10.8M
Stockholders' Equity
FUSB
FUSB
RNA
RNA
Q4 25
$105.6M
Q3 25
$104.2M
$1.9B
Q2 25
$101.9M
$1.2B
Q1 25
$101.2M
$1.3B
Q4 24
$98.6M
$1.4B
Q3 24
$98.5M
$1.5B
Q2 24
$93.8M
$1.2B
Q1 24
$92.3M
$830.9M
Total Assets
FUSB
FUSB
RNA
RNA
Q4 25
$1.2B
Q3 25
$1.1B
$2.1B
Q2 25
$1.1B
$1.4B
Q1 25
$1.1B
$1.5B
Q4 24
$1.1B
$1.6B
Q3 24
$1.1B
$1.6B
Q2 24
$1.1B
$1.3B
Q1 24
$1.1B
$951.5M
Debt / Equity
FUSB
FUSB
RNA
RNA
Q4 25
0.10×
Q3 25
0.10×
Q2 25
0.11×
Q1 25
0.11×
Q4 24
0.11×
Q3 24
0.11×
Q2 24
0.12×
Q1 24
0.12×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FUSB
FUSB
RNA
RNA
Operating Cash FlowLast quarter
$12.3M
$-156.2M
Free Cash FlowOCF − Capex
$9.1M
$-156.9M
FCF MarginFCF / Revenue
87.2%
-1257.6%
Capex IntensityCapex / Revenue
31.1%
5.7%
Cash ConversionOCF / Net Profit
5.79×
TTM Free Cash FlowTrailing 4 quarters
$16.0M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FUSB
FUSB
RNA
RNA
Q4 25
$12.3M
Q3 25
$4.2M
$-156.2M
Q2 25
$3.9M
$-199.7M
Q1 25
$1.8M
$-124.8M
Q4 24
$7.8M
$-99.9M
Q3 24
$1.9M
$-65.6M
Q2 24
$2.5M
$-65.0M
Q1 24
$825.0K
$-70.4M
Free Cash Flow
FUSB
FUSB
RNA
RNA
Q4 25
$9.1M
Q3 25
$3.6M
$-156.9M
Q2 25
$1.6M
$-203.0M
Q1 25
$1.7M
$-128.6M
Q4 24
$5.7M
$-103.8M
Q3 24
$1.3M
$-67.3M
Q2 24
$2.3M
$-65.5M
Q1 24
$-142.0K
$-71.3M
FCF Margin
FUSB
FUSB
RNA
RNA
Q4 25
87.2%
Q3 25
34.2%
-1257.6%
Q2 25
16.0%
-5277.1%
Q1 25
17.2%
-8174.3%
Q4 24
58.2%
-3491.0%
Q3 24
12.7%
-2881.8%
Q2 24
23.5%
-3204.6%
Q1 24
-1.4%
-2012.3%
Capex Intensity
FUSB
FUSB
RNA
RNA
Q4 25
31.1%
Q3 25
5.9%
5.7%
Q2 25
21.8%
86.9%
Q1 25
0.7%
238.6%
Q4 24
21.6%
131.7%
Q3 24
6.6%
72.9%
Q2 24
2.0%
26.0%
Q1 24
9.8%
25.8%
Cash Conversion
FUSB
FUSB
RNA
RNA
Q4 25
5.79×
Q3 25
2.18×
Q2 25
25.16×
Q1 25
0.99×
Q4 24
4.53×
Q3 24
0.87×
Q2 24
1.20×
Q1 24
0.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons